In order to confirm whether the P-cadherin switch in accordance with high myosin II-B expression effectively acts in melanoma patients, we evaluated nodular melanomas for P-cadherin and myosin II-B positivity, because of the deep infiltrative nature of this melanoma subtype. Here, CDH3 is linked to nodular malignant melanoma.